Disease · MONDO_0006559
Comparisons in its trials27
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 27
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Adalimumab vs Placebo: deaths from any cause | 2 of 103 | 0 of 103 | 206 | NCT02808975 | Trial comparisons |
| Adalimumab vs Placebo: serious adverse events | 7 of 103 | 3 of 103 | 206 | NCT02808975 | Trial comparisons |
| MEDI8968 vs Saline: serious adverse events | 2 of 55 | 2 of 54 | 109 | NCT01838499 | Trial comparisons |
| Ruxolitinib 1.5% Cream BID vs Vehicle Cream BID: deaths from any cause | 0 of 66 | 0 of 35 | 101 | NCT05635838 | Trial comparisons |
| Ruxolitinib 1.5% Cream BID vs Vehicle Cream BID: serious adverse events | 2 of 66 | 1 of 35 | 101 | NCT05635838 | Trial comparisons |
| ATI-450 vs Placebo: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 35 of 48 | 26 of 47 | 95 | NCT05216224 | Trial comparisons |
| ATI-450 vs Placebo: deaths from any cause | 0 of 48 | 0 of 47 | 95 | NCT05216224 | Trial comparisons |
| ATI-450 vs Placebo: serious adverse events | 0 of 48 | 1 of 47 | 95 | NCT05216224 | Trial comparisons |
Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID vs DBVC Period: Vehicle Cream BID: Number of Participants With Any Treatment-emergent Adverse Event (TEAE ) in the Double-blind, Vehicle-controlled (DBVC) Period | 13 of 34 | 15 of 35 | 69 | NCT05635838 | Trial comparisons |
| Double-blind, Vehicle-Controlled (DBVC) Period: Ruxolitinib 1.5% Cream BID vs DBVC Period: Vehicle Cream BID: Number of Participants With Any Grade 3 or Higher TEAE in the DBVC Period | 0 of 34 | 2 of 35 | 69 | NCT05635838 | Trial comparisons |
| Period 1: CJM112 High Dose vs Period 1: Placebo: Clinical Responder Rate at Period 1: Week 16 | 10 of 31 | 4 of 32 | 63 | NCT02421172 | Trial comparisons |
| OLE Period: Ruxolitinib 1.5% Cream BID vs OLE Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID: Number of Participants With Any TEAE in the Open-label Extension (OLE) Period | 8 of 24 | 15 of 32 | 56 | NCT05635838 | Trial comparisons |
| OLE Period: Ruxolitinib 1.5% Cream BID vs OLE Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID: Number of Participants With Any Grade 3 or Higher TEAE in the OLE Period | 0 of 24 | 3 of 32 | 56 | NCT05635838 | Trial comparisons |
| Spesolimab vs Placebo: deaths from any cause | 0 of 36 | 0 of 16 | 52 | NCT04762277 | Trial comparisons |
| Spesolimab vs Placebo: serious adverse events | 0 of 36 | 1 of 16 | 52 | NCT04762277 | Trial comparisons |
| Prior Spesolimab (PS) vs Prior Placebo (PP): Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 28 of 30 | 15 of 15 | 45 | NCT04876391 | Trial comparisons |
| Prior Spesolimab (PS) vs Prior Placebo (PP): deaths from any cause | 0 of 30 | 0 of 15 | 45 | NCT04876391 | Trial comparisons |
| Prior Spesolimab (PS) vs Prior Placebo (PP): serious adverse events | 6 of 30 | 4 of 15 | 45 | NCT04876391 | Trial comparisons |
| Group A: Bermekimab 400 Milligram (mg) (Anti-Tumor Necrosis Factor [TNF] Failed) vs Group B: Bermekimab 400 mg (Anti-TNF Naive): Number of Participants With Adverse Events | 21 of 24 | 16 of 18 | 42 | NCT03512275 | Trial comparisons |
| Group A: Bermekimab 400 Milligram (mg) (Anti-Tumor Necrosis Factor [TNF] Failed) vs Group B: Bermekimab 400 mg (Anti-TNF Naive): deaths from any cause | 0 of 24 | 0 of 18 | 42 | NCT03512275 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006559/comparisons